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Aim: Alpha 1-adrenergic blocker (αb) remains the first line therapy in men with lower 
urinary tract symptoms (LUTS).  The current literature advocates continued use of α
b for their effect to be maintained. However, some patients decide to discontinue use of 
the medication after their symptoms are relieved and can keep good conditions.  In this 
study, we investigated the natural course of LUTS after the discontinuation of 
successful treatment of αb.  
Patients and methods: Among 75 patients with LUTS who stopped αb medication 
once their symptoms improved, 60 patients (aged 50 to 87 years old, with a median of 
70) who could be followed for at least 12 months after discontinuation of αb were 
enrolled analyzed in this study.  Evaluations included a clinical determination of the 
International Prostate Symptom Score (IPSS), peak flow rate (Qmax), and post-void 
residual urine volume (PVR).  Upon patient request or in cases of PVR more than 
100ml, administration of αb was resumed. 
Results: Eighteen out of the 60 patients (30%) asked for re-treatment within 12 months 
after discontinuation (re-treatment group). Other 42 patents could maintain the good 
condition without medication (discontinuation group).  IPSS was 15.9, 8.7, 10.1, 10.2, 
9.7, 8.8, 9.0, on the first visit, just before discontinuation, and 1, 3, 6, 9 and 12 months 
after stopping treatment among the discontinuation group, respectively.  Similarly, 
Qmax was 10.6, 14.8, 14.2, 14.3, 14.7, 13.2, 13.6 ml/sec., respectively.  Treatment 
periods, prostatic volume and peak flow rates just before discontinuation of medication 
differed significantly between the re-treatment and discontinuation group.  
Conclusions: In spite of the short follow-up periods, these results suggest that selected 
patients with relatively small prostatic volume and good flow rates after therapy can 
discontinue αb medication after their symptoms improve.  
 
INTRODUCTION 
Benign prostatic hyperplasia (BPH) is a major problem for many elderly men.  
An enlarged prostate associated with moderate to severe lower urinary tract symptoms 
(LUTS) and / or a decreased urine flow occurs in approximately 25% of men at 55 years 
old and this incidence increases linearly to 50% in men at 75 years old.1,2  It has been 
widely accepted that α1-adrenergic blockers are useful in the treatment of BPH 
because they reduce urethral resistance by relaxation of the prostate smooth muscle, 
acting on the dynamic component of obstruction.3,4  The median probability for 
symptomatic improvement with α1-adrenergic blocker therapy was found to be 74%.5  
The current literature advocates continued use of α1-adrenergic blockers for their 
effect to be maintained.6  However, some patients decide to discontinue use of the 
medication after their symptoms are relieved.  Verhamme et al. reported that a quarter 
of patients discontinued α1-adrenergic blockers very rapidly.7  To our knowledge, the 
point at which to discontinueα1-adrenergic blockers and the time for which sustained 
therapeutic efficacy remains after discontinuation have not yet been determined.  In 
this study, we assessed the natural course of lower urinary tract symptoms (LUTS) 
suggestive of BPH following discontinuation of α1-adrenergic blockers. 
 
PATIENTS AND METHODS 
This study was performed between October 2002 and June 2004.  Seventy five men 
with LUTS who reported improvement in subjective symptoms and post-voided 
residual urine volume (PVR) lower than 50ml after α1-adrenergic blockers treatment 
and wanting to discontinue medication were enrolled.    
Inclusion criteria included post-voided residual urine volume (PVR) lower than 50ml 
and the patient wanting to discontinue medication after their symptoms were relieved. 
Among the 75 patients with BPH who accepted to stop α1- adrenergic blocker 
medication once their symptoms improved, 60 patients (aged 50 to 87 years old, with a 
median of 70) who could be followed for at least 12 months after discontinuation of the 
medication were investigated in this study (Table 1).  The medication period just 
before discontinuation ranged from 2 to 200 months (median 14 months).  Treatment 
at the time of discontinuation consisted of 25 or 50 mg naftopidil daily in 32 patients, 
0.2 mg tamsulosin in 21 patients and 30 mg urapidil two times daily in 7 patients.  
Estimation of prostatic volume was used transabdominal ultrasonography.  The 
prostate was scanned in the transverse and sagittal directions with the patient in supine 
position. Prostate volume was determined using the following formula: width×length 
×height×0.52.  Patients who had an elevated serum PSA level were confirmed as 
BPH before the treatment by transrectal ultrasonography guided prostate sextant 
biopsies.  Evaluations included clinical determination of the International Prostate 
Symptom Score (IPSS), peak flow rate (Qmax), and PVR measured before and 1, 3, 6, 9, 
and 12 months after treatment had ended.  When patients wanted medication or PVR 
was more than 100ml, administration of α1-adrenergic blocker was resumed.  All 
patients provide informed consent before joining the study. 
All results are expressed as the mean ± SD.  The Wilcoxon signed rank test was 
used to evaluate intra-group differences and the Mann-Whitney U test was used for 
inter-group comparisons.  P values of less than 0.05 were considered significant. 
 
RESULTS 
Eighteen out of 60 patients (30%) reported worsening of symptoms after the 
discontinuation of treatment and they asked for treatment to be resumed: 10, 3, and 5 
patients restarted medication within 1, 6, and 12 months after discontinuation, 
respectively (re-treatment group).  *No patients were found to have PVR more than 
100ml during the follow-up period in the re-treatment group.  Other 42 out of 60 
patents (70%) could maintain the good condition without medication (discontinuation 
group).  IPSS was 15.9±6.8, 8.7±4.3, 10.1±6.1, 10.2±6.1, 9.7±5.6, 8.8±5.3, 9.0±5.4, on 
the first visit, just before discontinuation, and 1, 3, 6, 9 and 12 months after being 
stopped treatment respectively among the discontinuation group (Fig. 1).  Similarly, 
Qmax was 10.6±4.5, 14.8±6.2, 14.2±6.3, 14.3±5.3, 14.7±7.7, 13.2±5.8, 13.6±5.0 ml/sec, 
respectively (Fig. 2).  Symptom scores did not change significantly after use of the 
medication ceased during at least 12 months of follow-up.  Qmax did not change 
significantly before the 6 month follow-up, but it was decreased 9 and 12 months after 
discontinuation.  Treatment periods, prostatic volume, PSA and peak flow rates just 
before discontinuation of medication differed significantly between the re-treatment and 
discontinuation group: 51.2±13.7 versus 20.2±4.2 months (p=0.016), 32.3±2.8 versus 
24.9±1.1 g (p=0.045), 3.55±0.7 versus 2.13±0.3 ng/ml (p=0.015) and 11.4±0.9 versus 
16.4±1.0 ml/sec (p=0.007) (Table 2).  However, other parameters including age, IPSS 
and QOL score (at first visit and just before discontinuation) did not differ between the 
two groups.  Among the re-treatment group, each parameter was compared between 
the time just before discontinuation and the time when the patients wanted medication.  
Although the IPSS and QOL scores increased significantly, the parameter of 
uroflowmetry did not change even when the patients wanted to resume medication 
(Table 3).  In this study, no patient with prostatic volume less than 25ml and Qmax at 




As pharmacotherapies for LUTS associated with BPH, α1-adrenergic blockers 
have seen wide use in recent years, thanks to the fast action and safety of these agents. 
They remain the first-line therapy for the majority of patients today.  The total 
symptom score following medication is improved by 30 to 45% and maximum urinary 
flow rate by 15 to 30% versus baseline.8 Alpha1-adrenergic blocker is considered to be 
a rather safe drug.  However, there are some shortcomings.  The primary adverse 
events reported with α1-adrenergic blocker therapy are orthostatic hypotension, 
dizziness, tiredness (asthenia), ejaculatory problems, and nasal congestion.  These are 
probably related to the blockade of α1-adrenoceptors in blood vessels, and can limit the 
usefulness of these agents for LUTS.  In addition, 15-20% of patients do not show any 
improvement.9,10 The withdrawal rate due to such adverse events or insufficient 
treatment efficacy ranges from 14% to 38%.7,11,12  In other studies the discontinuation 
rate of α1-adrenergic blockers was 60% to 64% after 3 years of follow-up.6,13  The 
reasons for discontinuation were adverse events, persistence of complaints, or resolved 
complaints. Moreover, a MTOPS study showed that α1-adrenergic blocker (doxazosin) 
delayed the time of acute urinary retention but did not reduce the overall risk, at least 
not among patients at high risk of progression.14  
   The BPH guideline currently available proposes a watchful waiting strategy for 
patients with mild or moderate symptoms.15 Watchful waiting is to be recommended for 
patients with minimal symptoms or moderate/severe symptoms with little impairment of 
quality of life. Several studies have been conducted regarding the natural course of 
patients after discontinuation of α 1-adrenergic blocker once their symptoms 
improved.16-18 Debruyne reported that LUTS did not return to baseline after withdrawal 
of terazosin.16 Kobayashi et al. also reported 68.9% patients could keep good condition 
at 24 weeks after discontinuation of tamslosin.19 On the other hand, Kaplan et al. and 
Yanardag et al. suggested that complete cessation of α1-adrenergic blocker led to 
relapse of both symptoms and impairment of urinary flow within 3 months.17,18 Kaplan 
et al. presumed that a 3-month dosing regimen might have been insufficient to obtain a 
longer effect in their paper.17  In our study, the medication period was 20.2 months 
among the discontinuation group.  However, that of the re-treatment group was longer 
(51.2 months).  The patients with a long-term medication period requested re-treatment 
significantly more frequently after discontinuation.  Even in the re-treatment group, the 
objective parameters including uroflowmetry did not change at the time they wanted to 
resume medications.  One of the reasons for requesting re-treatment might be anxiety 
about discontinuation stopping treatment after longer period medication. 
The patients in our study had relatively mild symptom and responded well to 
α1-adrenergic blocker.  Moreover, patients who did not want to discontinue were not 
entered in the study.  There is thus a possibility of patient selection bias.  We also 
stopped medication during some restricted periods.  So the range of medication periods 
was very wide.  These observations warrant further investigation.  Even so, 70% of 
patients maintained their condition without medication during at least one year 
follow-up.  Especially, all patients with prostatic volume less than 25ml and Qmax at 
the time of discontinuation more than 15ml/s could keep the good condition at least 
during 12 months after stopping medication.  We believe that these results represent 
useful information for patients who want to discontinue after their symptoms improve.   
In conclusion, these results suggest that selected patients with relatively small 
prostatic volume and good flow rates with therapy can discontinue α1-adrenergic 
blocker medication after their symptoms improve.  
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Table 1: Background of the 60 patients enrolled in the study  
 
Table 2: Comparison between re-treatment and discontinuation group 
 Asterisks, p<0.05 
 
Table 3: Change of parameters in re-treatment group 
Asterisks, p<0.05 
 
Figure 1: Changes in mean IPSS in discontinuation group 
Asterisks, p<0.05 
 
Figure 2: Changes in mean Qmax in discontinuation group 
 
 
